Q2 Earnings Forecast for Surmodics Issued By Zacks Research

Surmodics, Inc. (NASDAQ:SRDX) – Stock analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for shares of Surmodics in a research note issued on Tuesday, January 28th. Zacks Research analyst D. Dey now expects that the company will post earnings per share of ($0.05) for the quarter, up from their previous forecast of ($0.08). The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.21 EPS and Q3 2026 earnings at $0.20 EPS.

A number of other analysts have also recently weighed in on SRDX. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research note on Thursday. StockNews.com began coverage on shares of Surmodics in a research note on Sunday, January 26th. They issued a “hold” rating for the company. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Surmodics currently has a consensus rating of “Hold” and an average price target of $50.00.

Surmodics Trading Down 4.1 %

Shares of NASDAQ:SRDX opened at $34.04 on Friday. The business’s 50 day simple moving average is $38.70 and its 200 day simple moving average is $39.15. Surmodics has a 1 year low of $25.17 and a 1 year high of $42.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.96 and a quick ratio of 3.22. The company has a market capitalization of $486.43 million, a P/E ratio of -42.02 and a beta of 1.21.

Surmodics (NASDAQ:SRDX) last issued its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%.

Hedge Funds Weigh In On Surmodics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers lifted its holdings in shares of Surmodics by 4.4% during the fourth quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock valued at $802,000 after purchasing an additional 861 shares during the last quarter. Modus Advisors LLC purchased a new position in shares of Surmodics in the 4th quarter worth $40,000. Quest Partners LLC grew its stake in shares of Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after purchasing an additional 1,071 shares during the period. SG Americas Securities LLC grew its position in Surmodics by 22.1% during the fourth quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after buying an additional 1,255 shares during the period. Finally, R Squared Ltd purchased a new stake in shares of Surmodics in the 4th quarter worth $55,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Insider Buying and Selling at Surmodics

In related news, CFO Timothy J. Arens sold 7,009 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total transaction of $276,434.96. Following the completion of the sale, the chief financial officer now directly owns 70,350 shares in the company, valued at $2,774,604. This represents a 9.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 8.90% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).